Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells.

Vascular endothelial cells (EC) participate in the process of bone formation through the production of factors regulating osteoclast differentiation and function. In this study, we report the selective expression in primary human microvascular EC of Osteostat/TNF superfamily 18, a ligand of the TNF superfamily. Osteostat protein is detectable in human microvascular EC and is highly up-regulated by IFN-alpha and IFN-beta. Moreover, an anti-Osteostat antibody strongly binds to the vascular endothelium in human tissues, demonstrating that the protein is present in the EC layers surrounding blood vessels. Functional in vitro assays were used to define Osteostat involvement in osteoclastogenesis. Both recombinant and membrane-bound Osteostat inhibit differentiation of osteoclasts from monocytic precursor cells. Osteostat suppresses the early stage of osteoclastogenesis via inhibition of macrophage colony-stimulating factor-induced receptor activator of NF-kappaB (RANK) expression in the osteoclast precursor cells. This effect appears to be specific for the differentiation pathway of the osteoclast lineage, because Osteostat does not inhibit lipopolysaccharide-induced RANK expression in monocytes and dendritic cells, or activation-induced RANK expression in T cells. These findings demonstrate that Osteostat is a novel regulator of osteoclast generation and substantiate the major role played by the endothelium in bone physiology.

[1]  T. Miyata,et al.  Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.

[2]  S. Song,et al.  Identification of a ligand for glucocorticoid-induced tumor necrosis factor receptor constitutively expressed in dendritic cells. , 2003, Biochemical and biophysical research communications.

[3]  M. Byrne,et al.  CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. , 2002, Immunity.

[4]  C. Murphy,et al.  TNFα Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL. , 2002, Endocrinology.

[5]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[6]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[7]  T. Martin,et al.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.

[8]  Mallika Singh,et al.  An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis , 2003, Nature Biotechnology.

[9]  E. Jimi,et al.  Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. , 1999, Journal of immunology.

[10]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[11]  D. Brigstock.  Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61) , 2004, Angiogenesis.

[12]  M. Zaidi,et al.  Stimulation of osteoclastic bone resorption by hydrogen peroxide. , 1992, Biochemical and biophysical research communications.

[13]  Guo-liang Yu,et al.  Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand* , 1999, The Journal of Biological Chemistry.

[14]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[15]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[16]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[17]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[18]  A. Parfitt.  Osteoclast precursors as leukocytes: importance of the area code. , 1998, Bone.

[19]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[20]  Hong-Hee Kim,et al.  Tumor Necrosis Factor-α Supports the Survival of Osteoclasts through the Activation of Akt and ERK* , 2001, The Journal of Biological Chemistry.

[21]  T. Nechiporuk,et al.  ETL, a Novel Seven-transmembrane Receptor That Is Developmentally Regulated in the Heart , 2001, The Journal of Biological Chemistry.

[22]  C. Riccardi,et al.  A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Kwon,et al.  TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  Shi Wei,et al.  Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[25]  M. Lotz,et al.  The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. , 2001, Arthritis and rheumatism.

[26]  Y. Lee,et al.  Recombinant glucocorticoid induced tumor necrosis factor receptor (rGITR) induces NOS in murine macrophage , 2002, FEBS letters.

[27]  S. Niida,et al.  BriefDefinitive Report Essential Role of Macrophage Colony-Stimulating Factor in the Osteoclast Differentiation Supported by , 2022 .

[28]  S. Wahl,et al.  IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes. , 1992, Journal of immunology.

[29]  C. Heid,et al.  A novel method for real time quantitative RT-PCR. , 1996, Genome research.

[30]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Kozo Nakamura,et al.  RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.

[32]  H. Datta,et al.  Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. , 1992, Endocrinology.

[33]  D. Lacey,et al.  Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .

[34]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[35]  A. Gurney,et al.  Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR , 1999, Current Biology.

[36]  William Maloney,et al.  Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.

[37]  J. Tschopp,et al.  BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.

[38]  Y. Azuma,et al.  Tumor Necrosis Factor-α Induces Differentiation of and Bone Resorption by Osteoclasts* , 2000, The Journal of Biological Chemistry.

[39]  T. Martin,et al.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Moore,et al.  Interferon-κ, a Novel Type I Interferon Expressed in Human Keratinocytes* , 2001, The Journal of Biological Chemistry.

[41]  C. Sherr,et al.  Colony-Stimulating Factor 1 (Macrophage Colony-Stimulating-Factor) , 1991 .

[42]  A. Mukherjee,et al.  Tumor Necrosis Factor-α (TNF) Stimulates RANKL-induced Osteoclastogenesis via Coupling of TNF Type 1 Receptor and RANK Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[43]  H. Datta,et al.  Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Lambers,et al.  Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. , 1986, The EMBO journal.

[45]  M. Kirkland,et al.  Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). , 2000, Clinical science.

[46]  B. Kwon,et al.  Cloning and characterization of GITR ligand , 2003, Genes and Immunity.

[47]  T. Martin,et al.  A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. , 1998, Endocrinology.

[48]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[49]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[50]  I. Owan,et al.  Postmitotic osteoclast precursors are mononuclear cells which express macrophage-associated phenotypes. , 1994, Developmental biology.